By Bob Herman | January 14, 2015
Humana acknowledged late Tuesday it has an exclusive deal to offer Gilead Sciences' hepatitis C drugs to its members.
Humana CEO Bruce Broussard told investors in a breakout session that it has a pricing arrangement with Gilead, but he did not disclose what kind of discount the health insurer received for the pricey drugs. High specialty drug costs were part of the reason why Humana's profit was lower in the third quarter.
Continue reading...
Follow Bob Herman on Twitter: @MHbherman
Humana CEO Bruce Broussard told investors in a breakout session that it has a pricing arrangement with Gilead, but he did not disclose what kind of discount the health insurer received for the pricey drugs. High specialty drug costs were part of the reason why Humana's profit was lower in the third quarter.
Continue reading...
Follow Bob Herman on Twitter: @MHbherman
No comments:
Post a Comment